What is Arzeda?
Arzeda is at the forefront of leveraging computational power to design and manufacture proteins that contribute to human well-being and environmental sustainability. The company collaborates with Fortune 500 entities and industrial leaders to develop advanced products across the food & nutrition, advanced materials, and diagnostics & pharma industries. Arzeda's proprietary platform integrates physics-based computational protein design, machine learning, and laboratory automation, pushing the boundaries of biotechnology beyond naturally evolved solutions. This innovative methodology allows for the creation of novel proteins tailored for specific industrial applications, positioning Arzeda as a key player in the synthetic biology revolution.
How much funding has Arzeda raised?
Arzeda has raised a total of $91.7M across 6 funding rounds:
Series A
$15.2M
Debt
$350K
Debt
$599K
Series B
$33M
Other Financing Round
$38M
Private Equity
$4.5M
Series A (2017): $15.2M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Debt (2021): $599K supported by PPP
Series B (2022): $33M featuring Casdin Capital, Lewis & Clark Agrifood, OS Fund, Bioeconomy Capital, Conti Ventures, UMI, Circulate Capital, and Bunge Ventures
Other Financing Round (2024): $38M backed by Bunge Ventures, Sofinnova Partners, and Sucden
Private Equity (2025): $4.5M, investors not publicly disclosed
Key Investors in Arzeda
Casdin Capital
Casdin Capital is a venture capital firm specializing in life sciences innovation, with a particular focus on diagnostics and molecular information. They invest in pioneering companies that are shaping the future of healthcare and biotechnology.
Lewis & Clark Agrifood
Lewis & Clark Agrifood provides growth capital for the agrifood sector, aiming to enhance food, health, and sustainability through innovation in areas like AI, food technology, and plant science. They support market leaders driving productivity and resilience.
OS Fund
OS Fund invests in entrepreneurs commercializing breakthrough discoveries in fields such as genomics and synthetic biology, aiming to create a better future through visionary innovation.
What's next for Arzeda?
The recent major strategic investment signals Arzeda's transition into a scaling phase, likely focusing on expanding its manufacturing capabilities, accelerating product development pipelines, and broadening its market reach. With a robust foundation in computational protein design and a growing portfolio of applications, Arzeda is poised to capitalize on the increasing demand for sustainable and high-performance biomaterials and ingredients. Future strategic initiatives may involve further R&D into novel protein functionalities, forging new partnerships with key industry players, and potentially exploring new therapeutic or diagnostic applications. The company's trajectory suggests a continued emphasis on innovation and market penetration within the rapidly evolving biotechnology landscape.
See full Arzeda company page
